Table 1.
CEA and SLeX expression in gastric carcinoma tissues and association with clinicopathological data.
| CEA | SLeX | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neg. | 5-25% | 25-75% | >75% | P* | Neg. | 5-25% | 25-75% | >75% | P* | |
| Laurén classification | ||||||||||
| Intestinal (n=22) | 1 (4.5%) | 3 (13.6%) | 4 (18.2%) | 14 (63.6%) | 0.289 | 4 (18.2%) | 4 (18.2%) | 11 (50%) | 3 (13.6%) | 0.232 |
| Diffuse (n=5) | 0 (0.0%) | 0 (0.0%) | 3 (60.0%) | 2 (40.0%) | 0 (0.0%) | 0 (0.0%) | 4 (80.0%) | 1 (20.0%) | ||
| Unclassified (n=24) | 0 (0.0%) | 1 (4.2%) | 10 (41.7%) | 13 (54.2%) | 3 (12.5%) | 4 (16.7%) | 8 (33.3%) | 9 (37.5%) | ||
| Carneiro classification | ||||||||||
| Glandular (n=22) | 1 (4.5%) | 3 (13.6%) | 4 (18.2%) | 14 (63.6%) | 0.481 | 4 (18.2%) | 4 (18.2%) | 11 (50%) | 3 (13.6%) | 0.476 |
| Mixed (n=24) | 0 (0.0%) | 1 (4.2%) | 10 (41.7%) | 13 (54.2%) | 3 (12.5%) | 4 (16.7%) | 8 (33.3%) | 9 (37.5%) | ||
| Isolated cells (n=4) | 0 (0.0%) | 0 (0.0%) | 2 (50.0%) | 2 (50.0%) | 0 (0.0%) | 0 (0.0%) | 3 (75.0%) | 1 (25.0%) | ||
| Solid (n=1) | 0 (0.0%) | 0 (0.0%) | 1 (100%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100%) | 0 (0.0%) | ||
| Ming classification | ||||||||||
| Expansive (n=18) | 1 (5.6%) | 2 (11.1%) | 6 (33.3%) | 9 (50%) | 0.344 | 5 (27.8%) | 6 (33.3%) | 5 (27.8%) | 2 (11.1%) | 0.008 |
| Infiltrative (n=31) | 0 (0.0%) | 2 (6.5%) | 9 (29.0%) | 20 (64.5%) | 2 (6.5%) | 1 (3.2%) | 17 (54.8%) | 11 (35.5%) | ||
| Unclassified (n=2) | 0 (0.0%) | 0 (0.0%) | 2 (100%) | 0 (0.0%) | 0 (0.0%) | 1 (50.0%) | 1 (50.0%) | 0 (0.0%) | ||
| Lymphatic invasion | ||||||||||
| Absent (n=12) | 0 (0.0%) | 2 (16.7%) | 5 (41.7%) | 5 (41.7%) | 0.419 | 3 (25.0%) | 0 (0.0%) | 6 (50.0%) | 3 (25.0%) | 0.130 |
| Present (n=39) | 1 (2.6%) | 2 (5.1%) | 12 (30.8%) | 24 (61.5%) | 4 (10.3%) | 8 (20.5%) | 17 (43.6%) | 10 (25.6%) | ||
| Venous invasion | ||||||||||
| Absent (n=21) | 0 (0.0%) | 4 (19.0%) | 9 (42.9%) | 8 (38.1%) | 0.022 | 4 (19.0%) | 4 (19.0%) | 9 (42.9%) | 4 (19.0%) | 0.656 |
| Present (n=30) | 1 (3.3%) | 0 (0.0%) | 8 (26.7%) | 21 (70.0%) | 3 (10.0%) | 4 (13.3%) | 14 (46.7%) | 9 (30.0%) | ||
| pTNM | ||||||||||
| I+II (n=30) | 1 (3.3%) | 3 (10.0%) | 12 (40.0%) | 14 (46.7%) | 0.329 | 6 (20.0%) | 4 (13.3%) | 13 (43.3%) | 7 (23.3%) | 0.470 |
| III+IV (n=21) | 0 (0.0%) | 1 (4.8%) | 5 (23.8%) | 15 (71.4%) | 1 (4.8%) | 4 (19.0%) | 10 (47.6%) | 6 (28.6%) | ||
| Total | 1 (2.0%) | 4 (7.8%) | 17 (33.3%) | 29 (56.9%) | 7 (13.7%) | 8 (15.7%) | 23 (45.1%) | 13 (25.5%) | ||
| Overall Survival | ||||||||||
| Average survival (months±SD) | ND | ND | 67.6 ± 12.7 | 58.6 ± 8.5 | 0.117 | 76.8 ± 19.3 | 78.2 ± 16.2 | 51.7 ± 10.6 | 82.3 ± 11.0 | 0.293 |
| 95% CI | ND | ND | 42.5 - 92.7 | 41.8 - 75.4 | 38.9 - 11.7 | 46.5 - 110.0 | 30.9 - 72.4 | 60.6 - 104.0 | ||